PIXITMEDIA
5.9.2022 16:34:37 CEST | Business Wire | Press release
pixitmedia1, a Kalray company, has announced today that pixstor™ and ngenea® (a shared storage and data orchestration solution) will be included in the content production area at the Amazon Web Services (AWS) stand (5.C80) at IBC 2022.
AWS will be showcasing a suite of end-to-end cloud production workflows, demonstrating how the industry’s leading tools for editing, compositing, finishing, grading and quality control (QC) can be used for full production in the cloud. These workflows will be supported by pixitmedia’s flagship products, pixstor and ngenea, software-defined storage and orchestration software.
This follows the announcement that pixitmedia has been accepted into the AWS Independent Software Vendor (ISV) Accelerate Program, a co-sell program for AWS Partners who provide software solutions that run on or integrate with AWS.
Offline editorial, visual effects (VFX) and color grading work is not only possible in the cloud, but can deliver huge and tangible benefits in performance, collaboration, scalability, and cost efficiencies for producers.
At IBC stand 5.C80, AWS will demonstrate the media creation lifecycle in five stages. Live camera footage will be ingested to a cloud collaborative environment using dailies platform Moxion. That footage will be edited in Adobe® Premiere® Pro and conformed in Flame®, Autodesk®'s finishing and VFX solution. A fourth stage will demonstrate FilmLight Baselight performing the color grade, and finally, the content will pass through Colorfront Streaming and Broker Service for QC, which also reads directly from Amazon S3.
The high-resolution, uncompressed 4K media for all five stages of the production process will be edited in place on the powerful media-centric storage infrastructure powered by pixstor and ngenea, with 10-bit uncompressed video streamed from applications running in the cloud to the stand. It will use the latest AWS Cloud Digital Interface (AWS CDI), NewTek Network Device Interface (NDI), and Colorfront Streaming and Broker Service technology, over a secure internet connection to an Amazon VPC. Amazon EC2 compute, Amazon Elastic Block Store and Amazon S3 storage underpin the entire pixstor and ngenea solution.
Ben Leaver, EVP of Business Development and Co-Founder of pixitmedia explains:
“We’re looking forward to being featured in the AWS stand at IBC to showcase our storage and data orchestration platform to the Media & Entertainment industry. Together with AWS and industry-standard software providers, we will demonstrate that high-end editorial, VFX and color grading work is possible in the cloud today. We are providing our customers with ease of use, guaranteed performance, greater collaboration and seamless workflows in the cloud.”
pixitmedia is a global member of the AWS Partner Network (APN) and an industry facilitator of cloud-enabled production workflows. pixstor offers AWS customers an agile storage environment that guarantees adaptability and performance. Coupled with the power of pixitmedia’s ngenea, it quickly and securely transports data to and from globally distributed cloud, object storage, and traditional network attached storage (NAS).
To learn more about pixitmedia at IBC 2022, click here
About pixitmedia
pixitmedia is a Kalray company (Euronext, ALKAL), a leading provider of hardware and software technologies and solutions for high-performance, data centric computing markets, from cloud to edge. pixitmedia and Kalray share a common vision and a complementary value proposition in both software and hardware to address today’s and tomorrow’s data-intensive world with solutions for a more intelligent, effective, energy-wise and user-friendly data-driven world.
pixitmedia facilitates seamless collaboration to enable the power of ideas. Our award-winning purpose-built, software-defined storage and data solutions simplify the flow of data to connect an increasingly complex world. Our aim is to deliver beyond expectations throughout all areas of our operation. We devise optimized solutions that give customers both choice and freedom, our restless innovation constantly pushes boundaries and the unrivalled care and knowledge of our team ensure optimum performance and value. Customer success is at the heart of our business, we have technical specialists and a unique, dedicated lab facility to guarantee the effectiveness of our solutions.
For more information, please visit: https://www.pixitmedia.com or email: marketing@pixitmedia.com
About Kalray
Kalray (Euronext Growth Paris - ALKAL) is a leading provider of hardware and software technologies and solutions for high-performance,
data-centric computing markets, from cloud to edge. Kalray provides a full range of products to enable smarter, more efficient, and energy-wise data-intensive applications and data center infrastructures.
Kalray’s offerings include its unique patented DPU (Data Processing Unit) processors and acceleration cards, as well as its leading-edge
software-defined storage and data management offers. Individually or combined, Kalray’s high-performance solutions allow its customers to improve the efficiency of data centers or design the best solutions in fast-growing sectors such as AI, Media & Entertainment, Life Science, Scientific Research, Edge Computing, Automotive and others.
Founded in 2008 as a spin-off of the well-known French CEA research lab, with corporate and financial investors such as Alliance Venture (Renault-Nissan-Mitsubishi), NXP Semiconductors and Bpifrance, Kalray is dedicated through technology, expertise and passion to offer more: more for a smart world, more for the planet, more for customers and developers. https://www.kalrayinc.com
1 pixitmedia is the dedicated branch for Media & Entertainment markets of arcapix Holdings Ltd, acquired by Kalray. See press release on March 3, 2022.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220905005287/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom